On the 12th, Pharma Research, led by CEO Sohn Ji-hoon, announced the publication of its '2025 Sustainability Management Report,' which comprehensively outlines its ESG (Environmental, Social, and Governance) strategy and key achievements from the previous year. This initiative reflects a strategic commitment to transparency with stakeholders including customers, shareholders, employees, partners, and local communities, crucial for enhancing brand trust and market reputation.

The report articulates the company's efforts to streamline its ESG operational framework to align with global standards while reinforcing its competitive edge in quality, ethics, and talent management. The structuring of this framework not only meets compliance requirements but also serves as a differentiator in a crowded market, where ESG initiatives increasingly drive consumer preferences and investment decisions.

Included in the report are six core issues identified through a materiality assessment: climate action, health and safety, product responsibility and quality, talent development, corporate governance, and compliance with ethical and legal standards. By addressing these aspects, Pharma Research demonstrates its proactive approach to mitigating risks and capitalizing on opportunities within the global market.

A significant focus of the report is the establishment of a global-level ESG framework. Pharma Research has revised its human rights declaration and policy to reflect international standards such as the Universal Declaration of Human Rights, along with new biodiversity and animal welfare policies. This indicates a strategic shift toward integrating comprehensive human rights considerations into its business operations, which is essential for stakeholder engagement and compliance in international markets.

In the environmental arena, the company achieved ISO 14001 certification for its environmental management system and implemented a greenhouse gas emissions control framework. These initiatives are designed to bolster production efficiency while achieving environmental goals, which are becoming critical for long-term brand viability and consumer loyalty in a sustainability-conscious economy.

Socially, Pharma Research has intensified its health and safety management systems across all operations and developed talent cultivation programs to enhance its human capital framework. This investment in talent is particularly significant as it establishes a sustainable growth model rooted in competent workforce management—a key driver for retention and organizational performance.

Pharma Research representatives stated that in the global market, product competitiveness is increasingly assessed alongside quality management, ethical operations, and supply chain robustness. By continuously enhancing its ESG governance models in line with global standards, Pharma Research aims to solidify its standing as a trusted player in the regenerative medicine sector, ultimately driving sustained business growth and establishing a resilient brand identity.